JMP Securities Boosts Halozyme Price Target On 'Long-Term Value' By: Benzinga via Benzinga June 04, 2015 at 10:17 AM EDT In a report published Thursday, JMP Securities analyst Jason N Butler maintained a Market Outperform rating on Halozyme Therapeutics, ... Read More >> Related Stocks: Baxter International Halozyme Therapeutic Johnson & Johnson Pfizer